Navigation Links
WuXi PharmaTech Completes Acquisition of AppTec

SHANGHAI, China, Jan. 31 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX) today announced the completion of its acquisition of AppTec Laboratory Services, Inc., a US-based service provider for the biopharmaceutical and medical device industries. AppTec offers testing, contract research and development, and cGMP biologics manufacturing services from a highly differentiated, fully integrated platform.

(Logo: )

The combined company brings together complementary service offerings and expertise to create a broad platform covering both chemistry and biologics, which allows WuXi PharmaTech to provide value-added services to our customers in the pharmaceutical, biotechnology and medical device industries.

"We are pleased to have completed this significant acquisition which immediately adds biologics capabilities and expertise to WuXi PharmaTech's existing capabilities, gains a significant U.S. operational footprint for WuXi PharmaTech and expands our U.S. customer base, with further opportunities to increase our market position," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "This acquisition further solidifies our leadership position as the premier and preferred drug R&D service partner for pharmaceutical, biotechnology and medical device companies."

"The management teams and dedicated employees of both companies are very enthusiastic about the prospects of the combined company," commented Mr. Edward Hu, COO of WuXi PharmaTech. "This is an acquisition of capabilities that we believe will drive our future growth by positioning WuXi as a high quality global drug R&D service collaborator with both small and large molecules expertise."

About WuXi PharmaTech

Founded in 2000, Shanghai-based WuXi PharmaTech is the leading China-based pharmaceutical and biotechnology R&D outsourcing company. As a research- driven and customer-focused company, WuXi PharmaTech provides pharmaceutical and biotechnology companies a broad and integrated portfolio of laboratory and research manufacturing services throughout the drug discovery and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. Its operations are grouped into two segments: laboratory services, consisting of discovery chemistry, service biology, analytical, pharmaceutical development and process development services, and research manufacturing, focusing on manufacturing of advanced intermediates and active pharmaceutical ingredients for R&D use. In 2007, its 80 customers included nine of the world's top ten pharmaceutical companies by revenue. For more information, please visit: .

For more information, please contact:

Hai Mi, Ph.D.

Vice President, Corporate Communications

WuXi PharmaTech Co., Ltd.

Tel: +86-21-5046-3726

Fax: +86-21-5046-3718


SOURCE WuXi PharmaTech
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
2. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
3. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
4. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
5. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
6. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
7. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
8. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
9. WuXi PharmaTech Announces Second Quarter 2007 Results
10. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
11. Max Nutrition, Inc. Completes Share Exchange with American Spring Pharmaceutical, Inc.
Post Your Comments:
(Date:11/24/2015)... 24, 2015 Capricor Therapeutics, Inc. ... the discovery, development and commercialization of first-in-class therapeutics, today ... Officer, is scheduled to present at the 2015 Piper ... a.m. EST, at The Lotte New York Palace Hotel ... . --> . ...
(Date:11/24/2015)... VILLAGE, Nev. , Nov. 24, 2015  PDL BioPharma, ... John P. McLaughlin , the company,s president and chief executive ... Jaffray Healthcare Conference next week in New York ... will occur on Tuesday, December 1, 2015 at 9:30 a.m. ... Presentations." Please connect to the website at least 15 minutes ...
(Date:11/24/2015)... ... November 24, 2015 , ... Whitehouse Laboratories is pleased to announce that ... facility will be strictly dedicated to basic USP 61, USP 62 and USP 51 ... to have complete chemistry and micro testing performed by one supplier. Management ...
(Date:11/23/2015)... Women with a certain type of lung nodule ... risk of lung cancer than men with similar nodules, according ... annual meeting of the Radiological Society of North ... --> Lung nodules are small masses of tissue ... based on their appearance on CT. Solid nodules are dense, ...
Breaking Biology Technology:
(Date:10/29/2015)... YORK , Oct. 29, 2015 ... technology, announced a partnership with 2XU, a global ... to deliver a smart hat with advanced bio-sensing ... and other athletes to monitor key biometrics to ... the strategic partnership, the two companies will bring together ...
(Date:10/27/2015)... BERLIN, Germany , October 27, 2015 ... 2015. SMI,s Automated Semantic Gaze Mapping technology (ASGM) automatically ... SMI,s Eye Tracking Glasses , so that ... Suite BeGaze. --> Munich, Germany ... technology (ASGM) automatically maps data from mobile eye tracking ...
(Date:10/26/2015)... India , October 26, 2015 ... --> adds ... 2015 to 2021 as well as ... 2015-2019 research reports to its collection ... . --> ...
Breaking Biology News(10 mins):